Which client statement regarding isoniazid (INH) for pulmonary tuberculosis would require follow-up?

The statement about taking isoniazid (INH) for three months requires follow-up because this duration is incorrect. Isoniazid is typically prescribed for a longer period when treating active pulmonary tuberculosis; the standard duration is usually six to nine months, depending on the specific treatment regimen and the individual circumstances of the patient.

In the other statements, the client demonstrates an understanding of important aspects of their treatment with isoniazid. The need for regular blood tests is a standard part of monitoring potential liver toxicity from the drug. Understanding that three negative sputum samples indicate non-infectiousness aligns with guidelines for tuberculosis treatment, confirming the effectiveness of the medication. Additionally, recognizing the side effects, such as potential numbness and tingling in the extremities, shows awareness of peripheral neuropathy, which can occur if vitamin B6 (pyridoxine) is not supplemented during treatment. This knowledge is vital for managing treatment and minimizing risks associated with isoniazid therapy.